AbbVie-3 Magnificent Stocks That Are Passive Income Machines

Core Viewpoint - The article highlights three dividend stocks—Abbott Laboratories, AbbVie, and Johnson & Johnson—as excellent options for passive income, emphasizing their strong dividend histories and solid business fundamentals. Group 1: Abbott Laboratories - Abbott Laboratories has a long history of dividend payments, dating back to 1924, and has increased its dividend for over 50 consecutive years [4] - The company currently pays a quarterly dividend of $0.59, which has risen by 146% over the past decade, averaging a compound annual growth rate of 9.4% [5] - Abbott's diverse operations across nutrition, diagnostics, pharmaceuticals, and medical devices contribute to its stability, with over$ 40 billion in revenue for the past four years and strong free cash flow of $6.7 billion [6][7] Group 2: AbbVie - AbbVie, spun off from Abbott in 2013, has maintained a strong dividend increase streak for 53 consecutive years, with a forward dividend yield of 3.64% [8] - The company has strategically invested in R&D and acquisitions, notably Allergan in 2020, to offset the decline in sales from its key drug Humira, which lost U.S. patent exclusivity in 2023 [9][10] - AbbVie's new drugs, Rinvoq and Skyrizi, are projected to generate combined sales of$ 31 billion by 2027, surpassing Humira's peak sales [10] Group 3: Johnson & Johnson - Johnson & Johnson is a leading healthcare company with a strong pharmaceutical business and a solid financial foundation, evidenced by its AAA credit rating from S&P Global [12] - The company has increased its dividends for 62 consecutive years, positioning it among the elite Dividend Kings, and is expected to continue this trend despite facing legal and regulatory challenges [13] - The defensive nature of the healthcare industry suggests that Johnson & Johnson will remain resilient during economic downturns, making it a strong choice for income-seeking investors [11]